Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX201 in Young Adults with Childhood Onset GHD
NCT00778518Phase 2Completed
- Sponsor
- Ambrx
- Start
- Jul 2008
- Primary completion
- Oct 2009
- Modality
- Recombinant Proteins and Enzymes, PEGylated Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of ARX201 in growth hormone deficiency (GHD), sponsored by Ambrx. Started Jul 2008; status: completed.
02
Drugs
ARX201
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT00778518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00778518.